Table 1.
Characteristics of NNRTIs approved by the European Union (EU) and/or the US Food and Drug Administration (FDA)
| Generic name (abbreviation) | Trade name | Manufacturer | Formulation | Date of FDA approval | Date of EU approval | |
|---|---|---|---|---|---|---|
| Nevirapine (NVP) | Viramune®
Viramune XR ® (extended release) |
Boehringer Ingelheim | • 200 mg tablet • Oral suspension (50 mg/5 mL) • 400 mg XR tablet |
21 Jun. 1996 XR tablet: 25 Mar. 2011 |
5 Feb. 1998 XR tablet: 21 Sept. 2011 |
|
| First-generation NNRTIs | Delavirdine (DLV) | Rescriptor® | Pfizer | 100 and 200 mg tablets | 4 Apr. 1997 | – |
| Efavirenz (EFV) | Sustiva® (FDA and EU) Stocrin® (EU) |
Bristol-Myers Squibb Merck Sharp and Dohme Ltd |
• 50, 100 and 200 mg capsules • 50, 200 and 600 mg tablets • Oral solution (30 mg/mL) |
17 Sept. 1998 |
28 May 1999 |
|
| Second-generation | Etravirine (ETR) | Intelence® | Janssen-Cilag | 100 and 200 mg tablets | 18 Jan. 2008 | 28 Aug. 2008 |
| NNRTIs | Rilpivirine (RPV) | Edurant® | Janssen-Cilag | 25 mg tablet | 20 May 2011 | 28 Nov. 2011 |